ANP Technologies, an emerging nanobiotechnology company, terminated the merger with Sorrento Therapeutics, an antibody-centric, clinical stage biopharmaceutical company. The effect of this termination now allows ANP to freely explore other business opportunities with parties interested in ANP’s diagnostic and platform drug delivery technologies.